Evidence that phosphoinositide metabolism in rat cerebral cortex stimulated by pilocarpine, physostigmine, and pargyline in vivo is not changed by chronic lithium treatment.
The effect of chronic versus acute administration of lithium on receptor-linked phosphoinositide metabolism was assessed by comparing the change in the cerebral cortex levels of myo-inositol 1-phosphate in response to pilocarpine, physostigmine, or pargyline in rats. Rats were exposed to either 29 consecutive days of LiCl injections or 27 and 39 days of dietary Li2CO3, followed by injected LiCl at the end of the diet to insure a constant level of exposure to the drug. In each experiment, an acute group received a single injection of LiCl 20-24 h before they were killed. One hour before being killed, some of the animals acutely exposed to lithium and some of the animals chronically exposed to lithium each received pilocarpine, physostigmine, or pargyline. At the conclusion of the experiment, the rats were killed and brain levels of myo-inositol 1-phosphate and lithium were determined. A differential production of myo-inositol 1-phosphate in groups receiving acute versus chronic lithium would provide evidence of a change in receptor-linked phosphoinositide metabolism due to the chronic administration of lithium. Brain levels of myo-inositol 1-phosphate are dependent on tissue lithium concentrations; consequently, significant differences observed in brain lithium levels between the groups receiving acute versus chronic lithium prevented a meaningful assessment of the effect of the mode of lithium administration on the production of myo-inositol 1-phosphate in those groups. Stepwise multiple regression analysis and the measured brain lithium levels were used to assess the response of myo-inositol 1-phosphate levels to stimulation in animals receiving acute or chronic lithium treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
Honchar
M P
MP
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110.
Vogler
G P
GP
Gish
B G
BG
Sherman
W R
WR
D000818:Animals; D002540:Cerebral Cortex / Q000378:metabolism*; D008094:Lithium / Q000494:pharmacology*; D008297:Male; D010293:Pargyline / Q000494:pharmacology; D010716:Phosphatidylinositols / Q000378:metabolism*; D010830:Physostigmine / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012044:Regression Analysis; D013268:Stimulation, Chemical; D013997:Time Factors
D010716:Phosphatidylinositols; D010862:Pilocarpine; D008094:Lithium; D010293:Pargyline; D010830:Physostigmine